Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2021.6036DOI Listing

Publication Analysis

Top Keywords

immune checkpoint
4
checkpoint inhibitor
4
inhibitor therapy
4
therapy toxicities-reply
4
immune
1
inhibitor
1
therapy
1
toxicities-reply
1

Similar Publications

Background Aims: Bulevirtide (BLV) is a novel and the only approved treatment option for patients with chronic hepatitis D (CHD). BLV alleviates liver inflammation already early during treatment when only minor HDV RNA changes are observed. We hypothesized that BLV-treatment may influence immune cells in CHD patients and performed a high-resolution analysis of natural killer (NK) cells before and during BLV-therapy.

View Article and Find Full Text PDF

Esophageal squamous cell carcinoma (ESCC) is a prevalent and highly lethal malignancy in Asia. Recent advancements in immune checkpoint inhibitors (ICIs) have markedly transformed the systemic therapy landscape for ESCC. Anti-PD-1-based combination with chemotherapy or with ipilimumab, an anti-CTLA-4 antibody, have been established as the new standard first-line treatments for patients with advanced ESCC.

View Article and Find Full Text PDF

EXO: A Dual-Mechanism Stimulator of Interferon Genes Activator for Cancer Immunotherapy.

ACS Nano

January 2025

Key Lab of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing 100084, China.

As natural agonists of the stimulator of interferon genes (STING) protein, cyclic dinucleotides (CDNs) can activate the STING pathway, leading to the expression of type I interferons and various cytokines. Efficient activation of the STING pathway in antigen-presenting cells (APCs) and tumor cells is crucial for antitumor immune response. Tumor-derived exosomes can be effectively internalized by APCs and tumor cells and have excellent potential to deliver CDNs to the cytoplasm of APCs and tumor cells.

View Article and Find Full Text PDF

NanoTrackThera Platform for Real-Time, In Situ Monitoring of Tumor Immunotherapy and Photothermal Synergistic Efficacy.

Small

January 2025

College of Chemistry, Chemical Engineering and Materials Science, Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Shandong Provincial Key Laboratory of Clean Production of Fine Chemicals, Shandong Normal University, Jinan, 250014, P. R. China.

Cancer is one of the leading causes of death worldwide, posing a significant threat to human health. Although immunotherapy has shown promise in cancer treatment, its efficacy is often compromised by tumor immune evasion, which hinders treatment outcomes. Therefore, combining immunotherapy with other therapeutic approaches to enhance its effectiveness has become an increasingly accepted strategy in clinical practice.

View Article and Find Full Text PDF

Objective: To assess 30- and 90-day postoperative complication rates in patients who underwent robot-assisted radical cystectomy (RARC) after receiving novel immunotherapy-based neoadjuvant treatment.

Methods: A bi-centre analysis was conducted in patients who underwent RARC with intracorporeal urinary diversion and who received an immunotherapy-based neoadjuvant regimen between 2017 and 2023. Complications were classified using the Clavien-Dindo system.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!